Influenza B virus
| Umifenovir | FLUBV | — | FDA approved | FDAChinaRussia | Human (multiple) | |
| Aprotinin | FLUBV | Serine protease inhibitor | Preclinical | — | Human (multiple) | |
| Azaribine | FLUBV | Inhibition of Viral Genome Replication | Preclinical | — | Viral RNA pol | |
| Baloxavir marboxil | FLUBV | Blocks intracellular viral RNA synthesis | FDA approved | FDAJapan | Viral endonuclease | |
| Brequinar | FLUBV | Inhibition of Viral Genome Replication | Preclinical | — | Human DHODH | |
| Camostat | FLUBV | — | Preclinical | — | Human protease | |
| Dapivirine | FLUBV | Non-nucleoside RT inhibitor | Preclinical | — | Unknown | |
| Favipiravir | FLUBV | Viral RNA polymerase inhibitor | FDA approved | FDAJapanChinaRussia | Viral RNA pol | |
| Ingavirin | FLUBV | Unknown | Approved (other) | Russia | Unknown | |
| Molnupiravir | FLUBV | Nucleoside analog | Approved (other) | Japan | Viral RNA pol | |
| Nafamostat | FLUBV | Synthetic serine protease inhibitor | Preclinical | — | Human protease | |
| Navitoclax | FLUBV | Bcl-2/Bcl-xL inhibitor | Preclinical | — | Human BCL2 | |
| Oseltamivir | FLUBV | Viral neuraminidase inhibitor | FDA approved | FDAJapanChina | Viral neuraminidase | |
| Pixavir marboxil | FLUBV | Cap-dependent endonuclease inhibitor | Approved (other) | China | CEN | NMPA 2025 CXHS2400073 |
| Sebaloxavir marboxil | FLUBV | PA endonuclease inhibitor | Approved (other) | China | PA | NMPA 2025 CXHS2400011 |
| Suraxavir marboxil | FLUBV | PA endonuclease inhibitor | Approved (other) | China | PA | NMPA 2025 CXHS2300106CXHB2400256 |
| Taribavirin | FLUBV | Human (multiple) | Preclinical | — | Viral RNA pol | |
| Teicoplanin | FLUBV | Peptidoglycan polymerization inhibitor | Preclinical | — | Human CTS | |
| Zanamivir | FLUBV | Neuraminidase inhibitor | FDA approved | FDAJapan | Viral neuraminidase | |
| Peramivir | FLUBV | Neuraminidase inhibitor | FDA approved | FDAJapan | Neuraminidase |